D. Western Therapeutics Institute (TSE:4576) ROCE % : -40.32% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is D. Western Therapeutics Institute ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. D. Western Therapeutics Institute's annualized ROCE % for the quarter that ended in Jun. 2024 was -40.32%.

D. Western Therapeutics Institute ROCE % Historical Data

The historical data trend for D. Western Therapeutics Institute's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D. Western Therapeutics Institute ROCE % Chart

D. Western Therapeutics Institute Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.42

-13.19

-6.47

-17.43

-33.48

D. Western Therapeutics Institute Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-23.01	-31.29	-64.06	-61.73	-40.32

D. Western Therapeutics Institute ROCE % Calculation

D. Western Therapeutics Institute's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-824.313	/	( ( (2956.376 - 211.207)	+	(2373.371 - 194.008) )	/ 2 )
	=	-824.313	/	( (2745.169	+	2179.363)	/ 2 )
	=	-824.313	/	2462.266
	=	-33.48 %

D. Western Therapeutics Institute's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-792.848	/	( ( (2117.369 - 154.727)	+	(2065.605 - 95.651) )	/ 2 )
	=	-792.848	/	( ( 1962.642	+	1969.954 )	/ 2 )
	=	-792.848	/	1966.298
	=	-40.32 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

D. Western Therapeutics Institute (TSE:4576) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

D. Western Therapeutics Institute ROCE % Related Terms

Thank you for viewing the detailed overview of D. Western Therapeutics Institute's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

D. Western Therapeutics Institute Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D. Western Therapeutics Institute Inc (TSE:4576) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6DW:Germany

Address

7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003

Website

http://www.dwti.co.jp

D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.

D. Western Therapeutics Institute Headlines

No Headlines